NICE Guideline CG192 - Antenatal and postnatal mental health: clinical management and service guidance
Refers to 3 formulations of valproate available in the UK: sodium valproate and valproic acid (licensed for the treatment of epilepsy) and semi?sodium valproate (licensed for the treatment of acute mania and continuation treatment in people whose mania responds to treatment). Both semi?sodium and sodium valproate are metabolised to valproic acid (also known as valproate), which is the pharmacologically active component. Valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place. This is because of the risk of malformations and developmental abnormalities in the baby. See update information for important safety advice from the MHRA on the use of valproate.